Prostate Cancer News - 2015-09-17
General Case Management
Targeted treatments help heal prostate cancer | WOODTV.com
The labyrinth called prostate cancer - The Sun Chronicle : Stories
Richard Tayson has prostate cancer. How he's been living with it for nine years says a lot about the state of the disease today.Knowing that aggressive treatment could mean urinary incontinence or erectile dysfunction, he found new doctors when those advocating surgery told him, "You can't make love if you're dead."
"It's a terrible decision to make; you feel doomed no matter what you do," Tayson said. "I'm walking around with cancer cells, but I'm handling it. If I make the wrong decision, I'm willing to live _ or die _ with it because I'm taking control of my situation."
That's just what the American Urological Association and the American Cancer Society, among other groups, want to see: informed men who get tested for prostate cancer and then carefully consider their options if signs point to disease. Both groups concede that men were overdiagnosed and overtreated when PSA screening was newer. That overtreatment gave rise to a kind of no-testing backlash and cynicism over whether the real motive was making money. Nevertheless, there is a danger.
Great news as Government signals backing for cancer plan - Cancer Research UK - Science blog
Finding answers amid prostate cancer confusion;
Israeli men at highest risk compared to those in 19 other countries to get prostate cancer - Business & Innovation - Jerusalem Post
Choices you Make
Lower Your Risk for Prostate Cancer | Spartanburg Regional Healthcare System - WYFF Home
some steps you can take to help prevent prostate cancer:- Maintain a healthy diet by eating more fish and limiting consumption of red meat and dairy products.
- Limit calcium intake to no more than 1,500 mg of calcium a day.
- Avoid tobacco.
- Limit alcohol to no more than one drink per day.
- Avoid over-supplementation with megavitamins.
Is stress killing men with localized prostate cancer (at least in Sweden)? | THE "NEW" PROSTATE CANCER INFOLINK
Prostate Cancer Death Risk Linked to Stress - Renal and Urology News
High stress levels are associated with an increased rate of prostate cancer (PCa)-specific mortality among men treated for clinically localized PCa, according to researchers.Michael Jan, MD, and collaborators at the Karolinska Institutet in Stockholm, Sweden, surveyed 4,105 men treated for clinically localized prostate tumors. Those with the highest levels of perceived stress had a 66% increased risk of PCa-specific mortality compared with men who had low stress levels, the investigators reported online ahead of print in the Scandinavian Journal of Urology. They also had a high frequency of grieving and sleep loss, as well as fewer people with whom to share their emotional problems, according to the investigators.
Screening and Diagnosis
Biopsies, Genomics and Pathology
Prostate cancer: Urinary PCA3 and TMPRSS2:ERG reduce the need for repeat biopsy : Nature Reviews Urology : Nature Publishing Group
Biopsy: Quick and easy prostate core assessment by VR-SIM : Nature Reviews Urology : Nature Publishing Group
New tool sharpens hunt for prostate cancer
Artemis guides the biopsy needle to the right location, and it has all the patient's data so it can put the needle back in the same place for future biopsies.The procedure, which is covered by insurance, is done as an outpatient and results are available within 24 to 48 hours. As with all prostate biopsies, bleeding and urinary tract infection are possible, he said.
Springhart calls Artemis a "game changer" in the way physicians biopsy and diagnose men with prostate cancer.
"Before, we overtreated prostate cancer a lot more," he said. "Now we have more information to better differentiate between those who need surgery and those who do not."
Camunas, division chief for acute care and general surgery at GHS, said his brother underwent a radical prostatectomy after his diagnosis eight years ago.
Had this technology been available then, he said, he might not have had to.
"Rather than just doing a random ultrasound biopsy that they do in the office, they used the Artemis and detected a suspicious nodule," he said. "Probably using ultrasound-guided biopsy, they would never have hit the thing. I was blessed."
Tests
Elevated PSA Doesn't Always Mean Prostate Cancer — BioPortfolio.com
Your Cancer Answers: Testing for prostate cancer
PSA screening and testing is a complicated issue that is best discussed with your physician if to screen or not. In the near future, hopefully there will be more refined and sensitive tests such as the PSA-3, TMPRSS2:ERG gene fusion product and 3Telsa MRI imaging that will increase the ability to screen and detect prostate cancer. Until these future tests are available the PSA and your physician are your best tools in prostate cancer. All of us at Marian Regional Medical Center are committed to continuing the fight against prostate cancer and all cancerous diseases.Marian Cancer Care is providing a free prostate cancer screening for men without health coverage and between the ages of 55 and 69 Sept. 19 9 to 11 a.m. at Mission Hope Cancer Center. Call 219-4673 to register as space is limited.
Despite rain, car show still manages to get men revved about prostate cancer testing
Detecting prostate cancer | Tribune Register
A new test to detect prostate cancer may reduce the need for invasive surgery. This new test that costs $10, not only detects the cancer but also tells the size of the tumor as well. This is likely to help in early detection of the cancer, reducing the number of patients afflicted by it.Prostate cancer test which detects tumour size could save thousands of lives - Telegraph
Johns Hopkins: ultrasensitive PSA after surgery predicts biochemical relapse | THE "NEW" PROSTATE CANCER INFOLINK
Imaging
Novel Technique May Improve Detection of Aggressive Prostate Cancer - Renal and Urology News
Treatment
10-year outcomes of men initially diagnosed with TxN+M0 prostate cancer in the PSA era | THE "NEW" PROSTATE CANCER INFOLINK
for men with N+ disease at the time of diagnosis, some form of immediate localized therapy will improve long-term survival as compared to simple systemic therapy. For the men who did receive such localized therapy (i.e., those in Groups A, B, C, and E), 10-year overall survival was achieved by about 74 percent of the group compared to about 37 percent of those (in Groups D and F) who did not.Active Surveillance
What percentage of prostate cancer patients are really good candidates for active surveillance? | THE "NEW" PROSTATE CANCER INFOLINKActive surveillance may be underused for men with localized prostate cancer
Surveillance a Good Option in Very Low-Risk Prostate Cancer | Cancer Network
Surgery
Radiation
Primary radiotherapy vs conservative management for localized prostate cancer-a population-based study.Saving Prostate Cancer Patients from Collateral Damage
Hormone
Neoadjuvant ADT prior to radical surgery in high-risk prostate cancer patients | THE "NEW" PROSTATE CANCER INFOLINKChemo
Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease : Nature Reviews Urology : Nature Publishing Group
The RTOG trial investigated the survival benefit of chemotherapy combined with androgen deprivation therapy (ADT) in patients with high-risk nonmetastatic prostate cancer after radiotherapy. However, the 10-year overall survival data showed no difference between treatments; thus, chemotherapy is unlikely to improve the overall survival in patients with nonmetastatic prostate cancer.New Techniques
FDA poised to OK new prostate cancer procedure | North Bay Business JournalSide Effects
The Facts About Prostate Cancer Surgery and Impotence
Advanced technology has improved prostate cancer surgery to reduce the risks of erectile dysfunction following the procedure. However, possible nerve damage during surgery can still cause impotence in some men. Urinary incontinence is another possible side effect.A man’s ability to obtain and maintain an erection after prostate cancer surgery may depend on age, sexual function before the operation, and whether certain nerves are cut during the procedure, according to the American Cancer Society. The organization stated that all men may experience some decrease in the ability to have an erection. But the younger the man, the better chances there are of maintaining the ability to have an erection.
Advanced/Recurrence
Creating New Tools to Guide Personalized Therapy in Advanced Prostate Cancer
Newswise — New Brunswick, N.J., September 14, 2015 – Rutgers Cancer Institute of New Jersey researcher Justin Drake PhD, has been awarded $450,000 in grants to support a pair of three-year projects aimed at developing biomarkers to predict disease progression and guide treatment strategies for advanced prostate cancer using a combination of laboratory cancer models, computational and targeted mass spectrometry approaches.New drug-like compounds may improve odds of men battling prostate cancer
Researchers at Southern Methodist University, Dallas, have discovered three new drug-like compounds that could ultimately offer better odds of survival to prostate cancer patients. The drug-like compounds can be modified and developed into medicines that target a protein in the human body that is responsible for chemotherapy resistance in cancers, said biochemist Pia D. Vogel, lead author on the scientific paper reporting the discovery.The Daily Targum :: Combined therapies show promise in treating prostate cancer
ADT is a hormonal treatment, he said. It reduces testosterone levels in the body, which normally affects the cancer.Combining this with chemotherapy was first proposed 10 years ago, DiPaola said. At the time, he chaired the Eastern Oncology Cooperative Group hosted by the National Cancer Institute. The group’s goal was to combine resources between different institutions to perform a national study.
Survival of men with mCRPC who receive no additional life-prolonging treatment | THE "NEW" PROSTATE CANCER INFOLINK
A new article in the Scandinavian Journal of
Urology provides us with some insight — from relatively recent data
— into the survival times of men with metastatic, castration-resistant prostate
cancer (mCRPC) after prior treatment with androgen deprivation therapy (ADT)
but who either decline or do not receive any further form of life-prolonging
therapy.
No comments:
Post a Comment